替莫唑胺联合贝伐单抗治疗老年患者恶性脑胶质瘤的临床疗效分析

Effect of bevacizumab combined with temozolomide on malignant glioma in the elderly

目的:探讨替莫唑胺联合贝伐单抗治疗老年患者恶性脑胶质瘤的临床效果及安全性。方法:选取2013~2015年我院收治的恶性脑胶质瘤老年患者55例,依据不同的治疗方案分为治疗组(n=30,采用放疗+替莫唑胺化疗+贝伐单抗治疗)和对照组(n=25,采用放疗+替莫唑胺治疗)。治疗6个月及12个月后,比较两组患者的临床疗效及不良反应的发生情况。结果:治疗组的有效率和疾病控制率显著高于对照组,差异有统计学意义(P<0.05),两组不良反应发生率差异无统计学意义(P>0.05)。结论:替莫唑胺联合贝伐单抗同步放疗治疗恶性脑胶质瘤的疗效优于单纯替莫唑胺放疗,且贝伐单抗安全性较高、副作用小,是一种可优先选择的治疗方法,值得临床推广。

Objective： To evaluate the effect and safety of bevacizumab combined with temozolomide on malignant glioma in the elderly.Methods： Fifty--five cases of elderly patients with malignant brain glioma from 2012 to 2015 were divided into treatment group （n = 30, temozolomide＋ chemotherapy ＋ bevacizumab） and control group （n = 25, radiotherapy ＋ temozolomide） according to the postoperative treatment.The occurrence of clinical efficacy and adverse reactions of two groups were analyzed after treatment for six and twelve months. Results：The effective rate and disease control rate in treatment group were higher than those in control group, the difference were statistically significant （P 〈0.05）, there were no significant differences in adverse reaction rate between two groups （P 〉0.05）.Conclusion： Bevacizumab combined with temozolomide and radiotherpy is safe and effective in elderly patients with malignant glioma,and is a priority choice of treatment method, is worthy of clinical promotion.